Lichenification occurs when repeated scratching or rubbing causes skin to thicken and become leathery. Certain skincare and ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

Several observational studies with biologics other than IL-23 inhibitors have suggested that it might be possible to prevent patients with plaque psoriasis from progressing to psoriatic arthritis ...

The condition is “high-risk” plaque, once narrowly defined as plaque built up in the arteries that is likely to rupture, possibly leading to an acute heart attack or sudden cardiac death.